Sarcomatoid Carcinoma of the Lung

This study conducted a comprehensive multi-omics analysis of pulmonary sarcomatoid carcinoma (PSC), a rare and aggressive lung cancer. Integrating whole-exome sequencing, transcriptomic, proteomic, and phosphoproteomic data from 86 patients, alongside single-cell RNA sequencing, researchers characterized this poorly understood disease. They identified an elevated ferroptosis suppression signature, making tumors vulnerable to targeting FTL and SLC3A2. The study also revealed distinct patient subtypes based on proteomic profiling and highlighted the role of epithelial-mesenchymal transition in tumor progression and immunotherapy resistance.

This study investigated oncogenic fusions in 11 unclassified pulmonary spindle cell tumors, aggressive neoplasms with limited treatment options. Using anchored multiplex PCR-based targeted RNA sequencing, researchers identified ALK gene fusions in two patients (18.2%), specifically PPFIBP1::ALK and SYCL3::ALK. Both tumors also exhibited positive ALK immunohistochemical staining, despite showing morphological heterogeneity. These findings expand the molecular spectrum of these rare tumors and highlight the importance of detecting ALK fusions, including those with uncommon partners.